Gapping down
In reaction to disappointing earnings/guidance: VRNT -13.9%, (also announces $150 mln share buyback program ), LNDC -12.6%, WPRT -7.2%,FORM -6.7%, LSTR -4.1%, VNCE -1.9%, PLAY -1.1%, WMS -1%, RH -0.8%
Select metals/mining stocks trading lower: GOLD -2%, ABX -1.8%, GDX-1.6%, GFI -1.3%, GLD -0.8%
Other news: CTRV -13.2% ( to offer shares of its common stock and warrants to purchase shares of its common stock in a 'best efforts' underwritten public offering ), OPK -9% (receives CRL from the FDA for RAYALDEE NDA), ACRX -8.2% (names Howard B. Rosen as CEO, effective April 1; postpones the the start of the Zalviso Phase 3 trial (IAP312) originally planned for1Q16 ), DV -7.4% (block trade pricing below yesterday's close), SPKE -4.4% (announces 1.5 mln secondary offering of class A common stock by selling stockholders), STOR -2.6% (commences secondary offering of ~33.3 mln common shares by selling shareholders)
Analyst comments: INOV -2% (downgraded to Underweight from Equal-Weight at Morgan Stanley), ACOR -2.5% (initiated with a Sell at Goldman)
In reaction to disappointing earnings/guidance: VRNT -13.9%, (also announces $150 mln share buyback program ), LNDC -12.6%, WPRT -7.2%,FORM -6.7%, LSTR -4.1%, VNCE -1.9%, PLAY -1.1%, WMS -1%, RH -0.8%
Select metals/mining stocks trading lower: GOLD -2%, ABX -1.8%, GDX-1.6%, GFI -1.3%, GLD -0.8%
Other news: CTRV -13.2% ( to offer shares of its common stock and warrants to purchase shares of its common stock in a 'best efforts' underwritten public offering ), OPK -9% (receives CRL from the FDA for RAYALDEE NDA), ACRX -8.2% (names Howard B. Rosen as CEO, effective April 1; postpones the the start of the Zalviso Phase 3 trial (IAP312) originally planned for1Q16 ), DV -7.4% (block trade pricing below yesterday's close), SPKE -4.4% (announces 1.5 mln secondary offering of class A common stock by selling stockholders), STOR -2.6% (commences secondary offering of ~33.3 mln common shares by selling shareholders)
Analyst comments: INOV -2% (downgraded to Underweight from Equal-Weight at Morgan Stanley), ACOR -2.5% (initiated with a Sell at Goldman)